Posted on Fri, May. 9, 2008
PolyMedix Inc. of Radnor said had been cleared to initiate human clinical studies in Canada on its PMX-30063, which it believes will be useful in treating systemic infections.
The stock was priced at $1 in early afternoon Nasdaq trading, up from yesterday's close of $0.92.
email this
print this
reprint or license this
